Results of Annual General Meeting 2010

Dec 11th, 2010

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that details of the resolutions and the proxies received in respect of each resolution considered by the Starpharma Holdings Limited Annual General Meeting are set out in the attached proxy summary. 


Read More

AGM 2010 Chairman's Address & CEO Presentation

Nov 11th, 2010

View the Chairman's address and CEO's presentations from the 2010 Annual General Meeting held on 11 November 2010.

AGM 2010 Chairman & CEO's Presentation ( pdf file, 1012kb)


Read More

Starpharma's Partner SSL acquired by Reckitt Benckiser

Nov 4th, 2010

Reckitt Benckiser has announced that it has completed its £2.5bn acquisition of SSL after gaining approval from more than 85% of SSL's shareholders by last Friday.  As a result, SSL is now formally part of Reckitt Benckiser and its leading global condom brand Durex will be added to Reckitt’s portfolio of health and personal care “Powerbrands” which include Nurofen, Strepsils and Clearasil.

Read More

Quarterly Cashflow Report - September 2010

Oct 25th, 2010

The cash balance at 30 September 2010 was $20.2m.  The Operating & Investing cash outflow of $2.4m for the quarter includes the set-up and upfront costs of the phase 2 bacterial vaginosis study for VivaGel® commenced in July.

Read More

Starpharma presents at ASX Small to Mid Caps conference, Hong Kong

Oct 20th, 2010

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.

Watch the presentation

Read More

Shareholder Update October 2010

Oct 1st, 2010


Read More

Starpharma Expands Lilly Partnership

Sep 30th, 2010

Starpharma today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.

The new agreement relates to a co-development program for one of Starpharma’s dendrimer-drug conjugates.

Read More

Starpharma annual report and full year financial results

Aug 25th, 2010

Starpharma today released its annual report and financial results for the year ended 30 June 2010.

Cash reserves of $22.8 million are a result of prudent management of cash, successful capital raising and continuing partnering revenues, and interest received throughout the year.

Read More

The 6th Bioshares 2010 Biotech Summit

Jul 27th, 2010

Abstract: While much has been communicated about Starpharma's Vivagel product and its application as a microbicidal condom coating, the company was asked to present on the rapidly strengthening interest in the use of the company's dendrimers for the application of drug delivery.

Download: Bioshares Issue 369 ( pdf file, 26kb)

Read More

Shareholder Update May 2010

Apr 29th, 2010


Read More

Shareholder Update February 2010

Feb 11th, 2010


Read More